

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 October 2023 (26.10.2023)



(10) International Publication Number
WO 2023/204721 A1

(51) International Patent Classification:
C07K 5/103 (2006.01) *G01N 33/574* (2006.01)
C12Q 1/37 (2006.01) *A61P 35/00* (2006.01)

(72) Inventors: **LESNER, Adam**; Ul. Zielone Wzgórze 35,
83-330 Pępowo (PL). **GRUBA, Natalia**; Ul. Bursztynowa
16, 84-242 Kębłowo (PL).

(21) International Application Number:
PCT/PL2023/050026

(74) Agent: **KAWCZYŃSKA, Marta**; Ul. Bluszczańska 73,
00-712 Warszawa (PL).

(22) International Filing Date:
19 April 2023 (19.04.2023)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(25) Filing Language: Polish


(26) Publication Language: English

(30) Priority Data:
P.440976 20 April 2022 (20.04.2022) PL

(71) Applicant: **URTESTE S.A.** [PL/PL]; Ul. Starodworska 1,
80-137 Gdańsk (PL).

(54) Title: COMPOUND - DIAGNOSTIC MARKER FOR KIDNEY CANCER, METHOD FOR DETECTING ENZYMATIC ACTIVITY, METHOD FOR DIAGNOSIS OF KIDNEY CANCER, KIT COMPRISING THE COMPOUND, USES OF THE COMPOUND AND METHOD FOR THE TREATMENT OF KIDNEY CANCER

Fig. 3



(57) Abstract: The invention relates to a novel chemical compound - a diagnostic marker for use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of kidney cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from kidney cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing kidney cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to kidney cancer and use of the compound for the diagnosis of kidney cancer. The invention also relates to the compound for use as a diagnostic marker of kidney cancer and a method for the treatment of kidney cancer

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

comprising a step of carrying out the method for the diagnosis of kidney cancer as defined above using the compound.